GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bioporto AS (OCSE:BIOPOR) » Definitions » Cyclically Adjusted Price-to-FCF

Bioporto AS (OCSE:BIOPOR) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Bioporto AS Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bioporto AS Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Bioporto AS's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioporto AS Cyclically Adjusted Price-to-FCF Chart

Bioporto AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioporto AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bioporto AS's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Bioporto AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioporto AS's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bioporto AS's Cyclically Adjusted Price-to-FCF falls into.


;
;

Bioporto AS Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Bioporto AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Bioporto AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.059/120.2000*120.2000
=-0.059

Current CPI (Mar. 2025) = 120.2000.

Bioporto AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.027 100.300 -0.032
201509 -0.022 100.200 -0.026
201512 -0.038 99.800 -0.046
201603 -0.032 100.200 -0.038
201606 -0.034 100.600 -0.041
201609 -0.031 100.200 -0.037
201612 -0.025 100.300 -0.030
201703 -0.036 101.200 -0.043
201706 -0.051 101.200 -0.061
201709 -0.038 101.800 -0.045
201712 -0.035 101.300 -0.042
201803 -0.067 101.700 -0.079
201806 -0.062 102.300 -0.073
201809 -0.046 102.400 -0.054
201812 -0.030 102.100 -0.035
201903 -0.067 102.900 -0.078
201906 -0.083 102.900 -0.097
201909 -0.089 102.900 -0.104
201912 -0.079 102.900 -0.092
202003 -0.080 103.300 -0.093
202006 -0.050 103.200 -0.058
202009 -0.022 103.500 -0.026
202012 -0.037 103.400 -0.043
202103 -0.077 104.300 -0.089
202106 -0.050 105.000 -0.057
202109 -0.053 105.800 -0.060
202112 -0.053 106.600 -0.060
202203 -0.061 109.900 -0.067
202206 -0.035 113.600 -0.037
202209 -0.021 116.400 -0.022
202212 -0.055 115.900 -0.057
202303 -0.079 117.300 -0.081
202306 -0.038 116.400 -0.039
202309 -0.036 117.400 -0.037
202312 -0.007 116.700 -0.007
202403 -0.055 118.400 -0.056
202406 -0.050 118.500 -0.051
202409 -0.061 118.900 -0.062
202412 -0.041 118.900 -0.041
202503 -0.059 120.200 -0.059

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bioporto AS  (OCSE:BIOPOR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Bioporto AS Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Bioporto AS's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioporto AS Business Description

Traded in Other Exchanges
N/A
Address
Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.

Bioporto AS Headlines

No Headlines